- Oops!Something went wrong.Please try again later.
But as Street experts see it, the jolt is far from lethal — it’s galvanizing.
By JPMorgan’s assessment, Apple’s FDA-sanctioned feature poses no competitive threat to iRhythm’s Zio XT or AT technology.
“We don’t see Apple turning the iWatch into a regulated medical device approved for clinical diagnosis,” the analyst said in a note. (See Marcus' track record here.)
“To be clear, the Apple Watch is approved for over-the-counter use and is not a continuous monitor.”
The FDA said the Apple Watch is not a replacement for traditional diagnostic or treatment methods. Should Apple pursue such a label and place itself in direct competition with iRhythm, the process could slow Apple’s rate of innovation and subject its products to FDA regulation, according to JPMorgan.
At present, its specialty in preliminary, OTC screenings is seen to complement iRhythm technology.
“Instead, we expect that greater consumer preliminary screening for heart arrhythmias will only expand the number of patients seeking medical diagnosis, which, in turn, would benefit iRhythm,” Marcus said.
“If anything, this news could be seen as a win for the company, as more patients will be able to check their own heartbeat and then go into the office to be prescribed a Zio in order to get a more comprehensive analysis of their heart health.”
At the time of publication, iRhythm shares were trading up more than 5 percent at $94.14.
Fitbit's 'Test' Will Come In The Second Half, Says Bearish BofA
Apple Debuts Faster, More Durable iPhones; New Watch Enters Medical Device Territory
Latest Ratings for AAPL
Bank of America
View More Analyst Ratings for AAPL
View the Latest Analyst Ratings
See more from Benzinga
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.